Moderna "Will Apply for Emergency Use Authorization Once Vaccine Efficacy Is Proven"

[Asia Economy Reporter Kiho Sung] Moderna, a US biotech company developing a vaccine for the novel coronavirus infection (COVID-19), announced that it plans to apply for Emergency Use Authorization (EUA) if the clinical trials demonstrate efficacy above a certain level.

On the 17th (local time), according to local media, St?phane Bancel, CEO of Moderna, stated, "If the independent safety monitoring board determines that the vaccine has 70, 80, or 90% efficacy based on early clinical results, we will consider applying for use authorization."

Bancel said, "If (the vaccine efficacy) reaches that level, it can save the lives of many high-risk patients, so we will consider applying for Emergency Use Authorization for a limited group."

Moderna expects early clinical results to be available as soon as October or November. Last month, Moderna began Phase 3 clinical trials involving 30,000 participants.

This content was produced with the assistance of AI translation services.